Scarica l'app Stockscreener
75.87
0.75%
-0.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.44
Aprire:
$76.62
Volume 24 ore:
5.35M
Relative Volume:
1.41
Capitalizzazione di mercato:
$44.03B
Reddito:
$6.07B
Utile/perdita netta:
$1.06B
Rapporto P/E:
40.95
EPS:
1.8527
Flusso di cassa netto:
$799.60M
1 W Prestazione:
-3.61%
1M Prestazione:
-9.51%
6M Prestazione:
-2.33%
1 anno Prestazione:
-0.17%
Intervallo 1D:
$75.51
$77.56
Intervallo di 1 settimana:
$74.66
$79.91
Portata 52W:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Is Edwards Lifesciences Corporation stock a smart retirement pickPortfolio Value Summary & Free Accurate Trade Setup Notifications - mfd.ru
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day - The AI Journal
Rhumbline Advisers Acquires 15,792 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025 - Yahoo Finance
Halper Sadeh LLC Encourages Edwards Lifesciences - GlobeNewswire
Edwards Lifesciences Corporation $EW Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Wells Fargo Raises Price Target for Edwards Lifesciences (EW) | - GuruFocus
Edwards Lifesciences Leans Into Growth After Strong Quarter - TipRanks
Edwards Lifesciences (EW): Truist Securities Maintains Hold Rati - GuruFocus
Edwards Lifesciences (EW) Analyst Ratings Update: Price Target L - GuruFocus
Edwards Lifesciences (NYSE:EW) Advances Structural Heart Solutions - Kalkine Media
Edwards Lifesciences Corp (NYSE:EW) Issues Upbeat Guidance - FXDailyReport.Com
Rothschild & Co Redburn Adjusts Edwards Lifesciences PT to $94 From $93, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences 2026 Growth Targets Achievable, RBC Says - marketscreener.com
Piper Sandler Raises Price Target for Edwards Lifesciences (EW) to $100 | EW Stock News - GuruFocus
Edwards focuses on earlier TAVR adoption - MedTech Dive
Stifel reiterates Buy rating on Edwards Lifesciences stock at $110 target - Investing.com
Wells Fargo Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
Truist Securities Adjusts Price Target on Edwards Lifesciences to $89 From $92, Maintains Hold Rating - marketscreener.com
Wells Fargo & Company Raises Edwards Lifesciences (NYSE:EW) Price Target to $100.00 - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Q4 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $100 From $96, Maintains Overweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $87 From $88, Maintains Market Perform Rating - marketscreener.com
Baird Adjusts Price Target on Edwards Lifesciences to $87 From $90, Maintains Neutral Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $95 From $108, Maintains Buy Rating - marketscreener.com
The Analyst Verdict: Edwards Lifesciences In The Eyes Of 21 Experts - Benzinga
BTIG Reiterates Buy Rating for Edwards Lifesciences (EW) | EW St - GuruFocus
Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback - Yahoo Finance
Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Strategic Investments - GuruFocus
Edwards Lifesciences Q4 Earnings Call Highlights - Yahoo Finance
Edwards Lifesciences earnings missed by $0.04, revenue topped estimates - Investing.com
Edwards Lifesciences (EW) Earnings Transcript - The Globe and Mail
Edwards Lifesciences misses EPS estimate by $0.04, surpasses revenue prediction - MassDevice
Edwards Lifesciences (NYSE:EW) Sees S&P 500 Trading Uptick, Guidance - Kalkine Media
Earnings call transcript: Edwards Lifesciences Q4 2025 misses EPS forecast By Investing.com - Investing.com Nigeria
Edwards Lifesciences (NYSE:EW) Updates Q1 2026 Earnings Guidance - MarketBeat
Earnings call transcript: Edwards Lifesciences Q4 2025 misses EPS forecast - Investing.com
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Edwards Lifesciences forecasts 2026 profit above estimates on heart devices strength - marketscreener.com
Edwards Lifesciences Q4 Earnings Decline, Revenue Rises; Q1 Guidance Set - marketscreener.com
Edwards Lifesciences shares rise 5% as strong guidance overshadows Q4 earnings miss - Investing.com
(EW) Edwards Lifesciences Corporation Expects Q1 Revenue Range $1.55B$1.63B - marketscreener.com
(EW) Edwards Lifesciences Corporation Expects Q1 Adjusted EPS Range $0.70$0.76 - marketscreener.com
Edwards Lifesciences Q4 Earnings Summary & Key Takeaways - Benzinga
Edwards Lifesciences earnings up next: Can TAVR momentum last? By Investing.com - Investing.com UK
Edwards Lifesciences earnings up next: Can TAVR momentum last? - Investing.com
Edwards Lifesciences is Now Oversold (EW) - Nasdaq
Insights Ahead: Edwards Lifesciences's Quarterly Earnings - Benzinga
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.15%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):